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Introduction: Many women experience emotional distress, depression and anxiety after a diagnosis of breast
cancer. Psychological stress and depression have been associated with hypothalamic-pituitary-adrenal (HPA) axis
dysregulation that may adversely affect immune system functioning and impact upon survival. This study
investigated the effects of a lifestyle intervention on indices of psychological health status, HPA axis regulation and
immune function in overweight women recovering from early-stage breast cancer treatment.
Methods: A total of 85 women treated for breast cancer 3 to 18 months previously were randomly allocated to a
6-month exercise and hypocaloric healthy eating program plus usual care or usual care alone (control group).
Women in the intervention group received three supervised exercise sessions per week and individualized dietary
advice, supplemented by weekly nutrition seminars. Depressive symptoms (Beck Depression Inventory version II:
BDI-II), perceived stress (Perceived Stress Scale: PSS), salivary diurnal cortisol rhythms; inflammatory cytokines
(IL-6 and Tumor necrosis factor-α), leukocyte phenotype counts, natural killer (NK) cell cytotoxicity and lymphocyte
proliferation following mitogenic stimulation were assessed at baseline and 6-month follow up.
Results: Compared with the control group, the intervention group exhibited a reduction in depressive symptoms
(adjusted mean difference, 95% confidence intervals (95% CI): −3.12, −1.03 to −5.26; P = 0.004) at the 6-month
follow-up but no significant decrease in PSS scores (−2.07, −4.96 to 0.82; P = 0.16). The lifestyle intervention also had
a significant impact on diurnal salivary cortisol rhythm compared with usual care alone, as evidenced by an increase
in morning salivary cortisol at the 6-month follow-up (P <0.04), indicating a change in HPA axis regulation. Women
in the control group had higher total leukocyte, neutrophil and lymphocyte counts in comparison to the
intervention group at the 6-month follow-up (P ≤0.05), whereas there was no difference in NK cell counts
(P = 0.46), NK cell cytotoxicity (P = 0.85) or lymphocyte proliferation responses (P = 0.11) between the two groups.
Conclusion: Our results show that the lifestyle intervention resulted in a reduction in depressive symptoms and a
normalisation of HPA axis regulation. Such changes could have important implications for long-term survival in
women recovering from early-breast cancer treatment.
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Many women experience emotional distress, depression
and anxiety after a diagnosis of breast cancer, which can
persist for prolonged periods, irrespective of the clinical
treatment outcome [1,2]. Studies show that a quarter of
breast cancer patients have clinically important levels of
emotional distress up to 12 months after treatment [3]
and almost 50% of women experience depression and/or
anxiety during this period [1]. Psychological stress and
depression have been associated with hypothalamic-
pituitary-adrenal (HPA) axis dysregulation in breast can-
cer survivors, including aberrations in diurnal cortisol
rhythm [4,5], and elevated levels of the inflammatory
cytokine IL-6 [6] that may impair immune system func-
tioning [7] and adversely impact upon survival [8,9].
The importance of healthy lifestyle behaviours to pre-
vent the adverse effects of weight gain after a breast can-
cer diagnosis is widely acknowledged and sustainable
lifestyle change was recently identified as one of the key
areas for future research [10]. Lifestyle interventions that
incorporate exercise and healthy eating advice could also
have an important role in modulating indices of psycho-
logical health status during the early recovery phase after
breast cancer treatment. Physical inactivity and poor
dietary habits are independently associated with depres-
sive symptoms in breast cancer survivors [11,12], whereas
evidence suggests that regular exercise [13] and positive
dietary change [14] can improve depressive symptoms and
psychological wellbeing. By improving psychological
health status, lifestyle interventions have the potential to
impact upon the HPA axis regulation and enhance im-
mune function in women recovering from breast cancer
treatment. This could improve long-term outcome, as res-
toration of immune function after treatment is predictive
of survival [15,16].
We recently reported the results of a randomised con-
trolled trial that investigated the effects of an exercise
and hypocaloric healthy eating intervention on body
weight and metabolic biomarkers associated with disease
recurrence in women recovering from early-stage breast
cancer treatment [17]. Women in the intervention group
experienced a wide range of health benefits, including
reductions in central adiposity, dietary fat intake, total
cholesterol and resting diastolic blood pressure and an
improvement in cardiopulmonary fitness [17]. Here, in
the same patient cohort, we report the effects of the life-
style intervention on indices of psychological health sta-
tus, HPA axis regulation and immune function.
Methods
Participant recruitment
This study recruited 90 overweight women with a body
mass index (BMI) >25 kg/m2, who had completed sur-
gery, chemotherapy and radiotherapy for early-stagebreast cancer (stage I to III) 3 to 18 months previously.
Biological samples were unavailable for five women in
the sample population, leaving an evaluable sample size
of 85 women. Patients receiving adjuvant endocrine
treatments were eligible, and those yet to complete a
one-year course of adjuvant trastuzumab were also in-
cluded, subject to acceptable cardiac function deter-
mined by a multi-gated acquisition (MUGA) scan and
consultant approval. Exclusion criteria included: con-
comitant hormone replacement therapy (HRT) or oral
contraceptives; metastatic or active loco-regional disease;
physical or psychiatric impairment limiting physical mo-
bility; severe nausea, anorexia or other conditions pre-
cluding participation in exercise, the consumption of
alternative/complementary diets or use of high-dose
antioxidant supplements; and those already engaged in
regular exercise. Patients were recruited from the Cancer
Clinical Trials Centre at Weston Park Hospital, Sheffield
UK or through local cancer support services, the local
media or word of mouth. Ethics approval was obtained
from the South Sheffield Research Ethics Committee
and all participants provided written informed consent
prior to the first assessment visit.
Sample size
Change in body weight was chosen as the primary out-
come variable for calculation of sample size [17]. Using
the data of Utter et al. [18], we estimated that recruitment
of 90 women (45 in each group) would give us 90% power
to detect a clinically meaningful reduction in body weight
between the groups at the two-sided α level of 0.05. In
addition, using Beck Depression Inventory II (BDI-II) data
from our previous exercise trial [13], a sample size of 38
patients per group gave us 80% power to detect a change
in BDI of 6 points at the alpha level of 0.05.
Randomisation and allocation concealment
Following the assessment of outcome variables at base-
line, patients were randomly allocated to one of two
groups: (i) lifestyle intervention (n = 44), or (ii) control
group (n = 41). The control group received a healthy eat-
ing booklet, Eat Well (Food Standards Agency, UK),
which also included brief advice on keeping active. Mini-
misation was used to balance the potentially confound-
ing variables of chemotherapy and treatment with
tamoxifen, aromatase inhibitors or no hormone therapy.
Randomisation was performed by an independent re-
searcher at the Clinical Trials Research Unit, University
of Leeds. The randomisation sequence was not disclosed
until patients had completed their baseline assessments.
Lifestyle intervention
Details of the pragmatic lifestyle intervention were pub-
lished previously [17]. Briefly, the 24-week lifestyle
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sions each week with an individually tailored hypocaloric
healthy eating programme. Exercise sessions (including
one to three women) comprised 30 minutes of aerobic
exercise (65 to 85% age-predicted maximum heart rate)
using one or more of a treadmill, cross-trainer, cycle erg-
ometer and/or rowing ergometer, followed by 10 to
15 minutes of muscle strengthening exercises using re-
sistance bands, hand weights and stability balls. Each
participant also received one-to-one individualized diet-
ary advice and written information (Weight Loss On A
Plate, Scottish Dietetic Association). The written infor-
mation included guidance on portion sizes for common
foods in each food group and a healthy eating plan. The
goal was to reduce the patient’s total daily calorie intake
to 600 kcal below their calculated energy requirements,
thereby inducing an estimated steady weight loss of up
to 0.5 kg each week. Additional weekly small-group nu-
trition education seminars included topics such as diet-
ary fat intake, hydration, achieving a healthy balanced
diet and alcohol consumption. In the control group,
contact with researchers was limited to assessment ses-
sions. Participants in the control group were offered
three exercise sessions at the university exercise research
facility and general exercise and dietary advice after the
final follow-up.
Outcome measures
Outcomes were assessed at baseline (pre-randomisation)
and at 24 weeks post randomisation in both groups.
Questionnaire outcomes (depressive symptoms and per-
ceived stress) were assessed by a trained technician who
was blinded to the group allocation. Saliva and blood
analytes were measured blindly by members of the re-
search team.
Depressive symptoms and perceived stress
Depressive symptoms were assessed using the BDI, Ver-
sion II© (BDI-II) [19], which has a range of 0 to 63, with
each item rated on a 4-point Likert-type scale ranging
from 0 to 3. Perceived stress was assessed using the per-
ceived stress scale (PSS) [20]. The scale was developed
to measure the extent to which respondents appraise sit-
uations in their life to be stressful during the past
month. The 14-item scale has a range of 0 to 56, with
items rated on a Likert-type scale ranging from 0 to 4,
and with higher scores indicating higher levels of per-
ceived stress.
Saliva and blood analysis
Saliva samples were collected using salivettes® (Sarstedt,
Leicester, UK) containing a piece of absorbance gauze, at
8 am, 12 noon, 5 pm and 9 pm over three consecutive
days and stored at 4°C until collection. Saliva samplesfrom each daily time point were pooled and mixed, be-
fore being cleared by centrifugation at 300 g for 10 mi-
nutes and stored for later analysis. Blood (15 to 20 mL)
was drawn from an antecubital vein between 8 and
10 am following a 12-hour overnight fast. Saliva samples
for analysis of diurnal cortisol rhythms and serum sam-
ples for analysis of inflammatory cytokines (IL-6 and
TNF-α) were stored at −80°C until analysis, with dupli-
cate baseline and post-intervention samples analysed in
the same batch. Analysis of lymphocyte phenotype and
function (T cell/natural killer (NK) cell phenotyping,
lymphocyte proliferation in response to phytohemagglu-
tinin (PHA) stimulation and NK cell cytotoxicity) were
commenced within 2 hours of blood collection and ana-
lysed in duplicate or triplicate. Full blood-count analyses
were undertaken in the Haematology Department of the
Sheffield Teaching Hospitals NHS Foundation Trust
UK. All other analyses were undertaken in the Biomed-
ical Research Centre Laboratory at Sheffield Hallam Uni-
versity UK, as described below.HPA axis modulation
Diurnal salivary cortisol concentrations were determined
using a high sensitivity ELISA kit (Salimetrics, Newmar-
ket, UK). The detection limit is 0.003 μg/dL and the
intra- and inter-assay coefficients of variation were 3.5%
and 5.1%, respectively. Salivary cortisol typically shows a
diurnal response, being higher in the morning and lower
in the evening. Hence, the area under the diurnal saliv-
ary cortisol curve (AUC) was calculated using the trap-
ezoidal rule. The inflammatory cytokines, IL-6 and
TNF-α, were measured using high-sensitivity ELISA
kits (R&D Systems, Oxon, UK). The inter- and intra-
assay precision was 7.8% and 7.4%, respectively for IL-
6 and 8.4% and 5.3%, respectively for TNF-α. The lower
limits of detection were 0.039 ρg/mL and 0.106 ρg/mL,
respectively.Lymphocyte phenotyping
Absolute counts of helper/inducer (CD3+CD4+) and
suppressor/cytotoxic (CD3+CD8+) T lymphocytes and
NK cells (CD3−CD16+CD56+) were determined using a
three-colour whole-blood staining technique (TriTest™
BD Biosciences, Oxon, UK). Briefly, whole blood (100 μl)
was incubated for 30 minutes at 4°C with 10 μl of
TriTest™ solution (three-colour direct immunofluores-
cence reagent) in TruCount™ tubes containing a prede-
fined number of lyophilized latex beads (BD Biosciences,
Oxon, UK), before the erythrocytes were lysed and the
sample analysed immediately using flow cytometry
(FAC-Sort flow cytometer with CELLQuest Pro data ac-
quisition and analysis software; BD Biosciences, Oxon,
UK).
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Details of the NK cell cytotoxicity assay have been pub-
lished previously [21]. Briefly, K562 cells (NK cell-
sensitive human erythroleukemic cell line) were grown
in RPMI 1640 (Gibco-BRL, UK), supplemented with
100 μg/mL streptomycin, 100 U/mL penicillin and 10%
fetal bovine serum (complete RPMI: cRPMI), before be-
ing labelled with the green fluorescent 3,3′-dioctadecy-
loxacarbocyanine perchlorate (DIOC18(3), Sigma-Aldrich
Ltd., Dorset, UK) at a concentration of 3 mM in di-
methyl sulfoxide (DMSO). Unfractionated peripheral
blood mononuclear cells (PBMCs) were used as the ef-
fector cell population. Peripheral blood was diluted 1:1
with 0.9% w/v NaCl and two volumes of the diluted
sample were layered over one volume of Nycoprep 1.077
(Axis-Shield Diagnostics Ltd., Huntingdon, UK). The
gradient mixture was centrifuged at 300 g for 30 minutes
and the PBMCs harvested from the interface. PBMCs
were then resuspended in cRPMI (5 × 106 cells/mL)
prior to their inclusion as effector cells in the NK cell
cytotoxicity assay. PBMC effector cells and DIOC18(3)-
labelled K562 target cells were mixed together at five ef-
fector:target (E:T) cell ratios: 50:1, 25:1, 12.5:1, 6.25:1
and 3.12:1, mixed thoroughly, pelleted by centrifugation
at 300 g for 1 minute and incubated for 3 hours at 37°C
in 5% CO2/95% air in a humid environment. The DNA
stain propidium iodide (PI; 10 μg/mL), used to label
non-viable cells, was then added immediately prior to
flow cytometry analysis for determination of the propor-
tion of live and dead K562 target cells at each E:T cell
ratio.
Lymphocyte proliferation assay
Lymphocyte proliferation was measured using bromo-
deoxyuridine (BrdU) incorporation during DNA synthe-
sis [22] after stimulation with the non-specific mitogen
PHA. PBMCs (50 μl of a 5 × 106 cells/mL suspension in
cRPMI) were added to the wells of a 96-well flat-bottom
tissue microtitre plate before mixing with 50 μl of PHA
at concentrations of 0 μg/mL (culture medium only),
0.1, 0.5, 1.0 and 10.0 μg/mL in cRPMI (final volume of
100 μl per well). Cultures (in triplicate) were incubated
at 37°C with 5% CO2 for 48 hours and proliferation was
assessed using a colorimetric BrdU immunoassay (BrdU
Cell Proliferation ELISA: Roche Diagnostics GmbH,
Mannheim, Germany). The mean optical density of
antigen-stimulated cultures/mean optical density of
medium-only cultures was determined for each culture
treatment and recorded.
Data analysis
Intention-to-treat analysis was used to compare patients
in the groups to which they were randomly assigned,
with missing data being imputed using the SPSS linearinterpolation procedure. Three women were lost to fol-
low up in each group. The Shapiro Wilk test was used
to check the normality of the data prior to data analysis,
with non-normally distributed variables log-transformed
to normality before analysis. Comparisons between the
groups were analysed using analysis of covariance
(ANCOVA), with baseline values used as the covariate.
Repeated measures ANOVA was used to assess for
changes from baseline within the groups. Unless other-
wise stated, normally-distributed data are presented as
mean ± SD and non-normally distributed data as median
(semi-interquartile range (SIQR)). Categorical data were
analysed using the chi-squared test (χ2). Statistical sig-
nificance throughout was taken at the two-sided 5% level
(P <0.05). All data were analysed using SPSS v19.0 (IBM,
Somers, NY, USA).
Results
The two groups were generally well-matched at baseline
for key demographic and anthropometric variables
(Table 1). In addition, levels of depression and perceived
stress were well-balanced across the two groups. Nearly
all the women were white Caucasian and on average,
were 7 to 9 months post-treatment. Compliance to the
supervised exercise sessions was excellent, with women
attending on average 84% (42 to 98%) of the sessions
that were offered to them.
Depressive symptoms were reduced in the intervention
group in comparison with controls at the 6-month
follow-up (P = 0.004). This was due to a greater reduc-
tion in BDI-II scores from baseline in the intervention
group (P <0.001) in comparison with the controls (P =
0.02; Table 2). A total of 15 (34%) of participants in the
intervention group were at least mildly depressed at
baseline (BDI-II ≥14 [19]), in comparison with 2 partici-
pants (4.5%) at the 6-month follow-up, whereas in the
control group the number of at least mildly depressed
participants remained constant (22%) throughout the
study period (χ2 = 5.93; P = 0.02). In contrast, the reduc-
tion in PSS score in the intervention group versus con-
trols at the 6-month follow-up was not significant (P =
0.16), despite a significant reduction from baseline PSS
score (P <0.001, Table 2).
A pronounced diurnal cortisol rhythm was evident at
baseline in both groups, with highest levels being re-
corded in the morning sample and lowest values in the
evening (Figure 1). Although a similar diurnal cortisol
rhythm was apparent in both groups at the 6-month
follow-up, an increase in diurnal salivary cortisol rhythm
AUC was observed in the lifestyle intervention group in
comparison with the controls (P = 0.03; Figure 2). This
was attributable to a higher post-intervention morning
salivary cortisol concentration (P = 0.03; Figure 1). In
contrast, the lifestyle intervention had no effect on
Table 1 Baseline characteristics of the two groups
Characteristic Intervention group (n = 44) Control group (n = 41)
Age, years 55.8 (10.0) 55.3 (8.8)
Body mass, kg 78.1 (10.1) 82.9 (17.0)
Body mass index, kg/m2 29.7 (3.5) 31.1 (5.7)
Waist circumference, cm 91.1 (9.9) 94.5 (13.8)
Waist:hip ratio 0.82 (0.07) 0.83 (0.06)
Months post treatment 9.0 (5.5) 7.1 (4.4)
Lymphoedema, n (%) 9 (20.4) 15 (36.6)
Ethnicity
White, n (%) 43 (98) 41 (100)
Marital status
Married/cohabitating, n (%) 29 (66) 29 (71)
Single/windowed/divorced, n (%) 15 (34) 12 (29)
Smokers, n (%) 3 (6.8) 1 (2.4)
Hormone treatment
Chemotherapy, n (%) 26 (59.1) 22 (53.7)
Radiotherapy, n (%) 38 (86.4) 33 (80.5)
Tamoxifen, n (%) 21 (47.7) 21 (51.2)
Arimidex, n (%) 14 (31.8) 10 (24.4)
Herceptin, n (%) 3 (6.8) 5 (12.2)
n, number.
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(P = 0.93) or TNF-α (P = 0.61; Table 2).
An increase in total leukocyte count in the controls in
comparison with the intervention group was observed
at the 6-month follow-up (P = 0.04; Table 3), attribut-
able to an increase in lymphocyte count (P = 0.04) and
neutrophil count (P = 0.05). The CD3+CD4+ and CD3+
CD8+ T cell counts showed a different pattern of response
between the two groups (P ≤0.05; Table 3). However,
the lifestyle intervention had no effect on CD4+:CD8+
T cell ratio (P = 0.87), NK cell count (P = 0.46), NK cell
cytotoxicity (P = 0.85) or lymphocyte proliferation in
response to PHA stimulation (P = 0.11; Table 3 and
Figure 2).
Discussion
Although pragmatic lifestyle interventions could be im-
portant for helping to prevent the adverse effects of
weight gain after breast cancer treatment [10], few stud-
ies have assessed the impact of combined exercise andTable 2 BDI-II and PSS scores at baseline and 6 months in the
Intervention group
Baseline Follow up Δ
BDI-II 11.3 (7.6) 5.1 (4.9) −6.1 (6.9)*
PSS 22.9 (7.2) 18.2 (7.7) −4.8 (7.9)*
BDI-II, Beck depression inventory-II; PSS, perceived stress scale; Δ, change from thehealthy eating programmes on psychological wellbeing
and associated prognostic biomarkers in breast cancer
survivors [23,24]. This is the first study to report the ef-
fects of a combined exercise and healthy eating interven-
tion on psychological health status, indices of HPA axis
regulation and immune function in overweight women
during the early recovery phase (3 to 18 months) after
stage-I to -III breast cancer treatment. There was excel-
lent compliance with the exercise sessions (84%) and
low attrition, with only three participants from each
group being lost to follow up in this analysis of psycho-
logical and neuro-immunological variables. An improve-
ment in depressive symptoms in the intervention group
was not accompanied by a significant reduction in per-
ceived stress. However, the lifestyle intervention also had
a significant impact on diurnal salivary cortisol rhythm,
as evidenced by an increase in morning salivary cortisol
at the 6-month follow-up.
At baseline, BDI-II depression scores in our patient
cohort were consistent with previous studies of breastlifestyle intervention and usual care control groups
Control group
Baseline Follow up Δ
* 10.2 (5.5) 7.9 (6.0) −2.3 (5.8)*
* 21.5 (5.6) 19.5 (6.8) −1.9 (6.8)
baseline score; *P <0.05; **P <0.01 in comparison with baseline (within groups).
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
8:00 AM 12:00 PM 5:00 PM 9:00 PM
Baseline 6 month follow-up
S
al
iv
ar
y 
co
rt
is
ol
 c
on
ce
nt
ra
tio
n 
(µ
g
/d
L)
 *
Lifestyle intervention group
Control group
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
8:00 AM 12:00 PM 5:00 PM 9:00 PM
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range (SIQR). *P = 0.03 for area under the curve (AUC) between groups.
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mean BDI-II depression score from baseline in the inter-
vention group was similar to that previously reported
following exercise interventions [25]. Improvements in
depression scores have also been observed after lifestyle
interventions involving a dietary component to promote
healthy eating and healthy body weight maintenance
[26,27] but this has not been a consistent finding [23].0.0
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at baseline [28], a reduction in BDI-II score >3 points is
clinically meaningful. Hence, the 6.1-point reduction
from baseline and between-group difference of >3 points
at the 6-month follow-up suggests that women in the
intervention group experienced a clinically important
change in depressive symptoms. Depressive symptoms in
women recovering from breast cancer treatment have3.12:1
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Table 3 Leukocyte counts and inflammatory cytokines at baseline and follow up
Intervention group Control group P-
valueBaseline Follow up Baseline Follow up
Leukocyte counts
Total leukocyte count (103 cells/μl) 5.145 (1.417) 5.156 (1.337) 5.184 (1.237) 5.594 (1.370) 0.04
Neutrophil count (103 cells/μl) 3.014 (1.119) 2.958 (1.135) 3.131 (0.912) 3.377 (1.061) 0.05
Monoctye count (103 cells/μl) 0.400 (0.370, 0.430) 0.400 0.360, 0.440 0.400 (0.350, 0.450) 0.400 (0.350, 0.450) 0.63
Lymphocyte count (103 cells/μl) 1.507 (0.414) 1.523 (0.389) 1.446 (0.497) 1.612 (0.449) 0.04
CD3+CD4+T cells (103cells/μl) 0.748 (0.596, 0.900) 0.682 (0.605, 0.759) 0.659 (0.532, 0.786) 0.763 (0.648, 0.878) 0.02
CD3+CD8+ T cells (103cells/μl) 0.474 (0.365, 0.583) 0.402 (0.334, 0.470) 0.360 (0.214, 0.506) 0.409 (0.322, 0.496) 0.05
CD4+:CD8+ ratio 1.62 (1.36, 1.88) 1.69 (1.40, 1.98) 1.93 (1.51, 2.35) 1.91 (1.49, 2.33) 0.87
NK cells (103 cells/μl) 0.200 (0.175, 0.225) 0.206 (0.177, 0.235) 0.176 (0.147, 0.205) 0.174 (0.144, 0.292) 0.46
Inflammatory cytokines
IL-6 (ρg/mL) 1.599 (1.259, 1.906) 1.692 (1.377, 2.007) 1.755 (1.456, 2.054) 1.942 (1.602, 2.282) 0.93
TNF-α(ρg/mL) 0.889 (0.779, 0.999) 0.916 (0.767, 1.065) 1.058 (0.895, 1.221) 0.992 (0.870, 1.114) 0.61
Data are presented as means (SD) or medians (semi-interquartile range). P-value shown for between-group comparisons. P-values in boldface significant at alpha
0.05. NK, natural killer.
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low libido, poor financial status and social support, and
a range of other psychological factors [2]. Physical in-
activity and poor dietary habits have also been independ-
ently associated with depressive symptoms in breast
cancer survivors [11,12].
Evidence suggests that lifestyle interventions, which
include support for exercise and dietary behaviour
change, may improve depressive symptoms by improving
mood, enhancing self-efficacy expectations, reducing in-
trusive thoughts about breast cancer and future morbid-
ity/mortality and buffering self-concept perceptions
[27,29]. Reductions in body weight and/or body fat and
improvements in cardiopulmonary fitness (as observed
in the intervention participants [17]) could also have a
positive impact on depression scores [30,31]. In addit-
ion, biological mechanisms, including the release of
monoamine neurotransmitters (that is, serotonin, dopa-
mine and norepinephrine) and endorphins during exer-
cise have been proposed to account for improvements in
depressive symptoms in physically active individuals
[32]. However, it is also important to be mindful of at-
tention effects on depression symptoms, as an improve-
ment in BDI-II score was previously reported in the
attention control arm of a short-term exercise trial in a
similar cohort of early-stage breast cancer patients [13].
The increased level of personal contact between the
intervention group and researchers is a potential limita-
tion of the present study, which needs to be taken into
consideration. In summary, continued research is neces-
sary to understand the extent to which such factors in-
fluenced the improvement in depressive symptoms in
the present study and the impact of changes on long-
term prognosis.Although the intervention group also exhibited a sig-
nificant reduction in PSS scores from baseline levels, the
smaller difference between groups at the 6-month
follow-up was not significant. PSS scores in our patient
cohort at baseline were comparable to those reported
previously for breast cancer survivors [33-37]. However,
the lack of effect on this outcome measure contrasts
with previously reported reductions (in the range of 4 to
9 points) following stress management and yoga inter-
ventions in early-stage breast cancer patients [33-36]. A
large proportion of breast cancer survivors are reported
to use complementary therapies (including exercise) to
manage stress [38], but only one previous study has re-
ported reductions in PSS scale scores following exercise
training [37]. The reduction in PSS scores after a 10-
week programme of aerobic and resistance exercise was
only marginally greater in this study than the non-
significant difference between groups in our patient
cohort at the 6-month follow-up. Hence, the lack of a
significant effect on perceived stress in the present study
may be a reflection of low statistical power for this
outcome.
The intervention had a significant impact on HPA axis
regulation, as evidenced by an increase in diurnal saliv-
ary cortisol rhythm at the 6-month follow-up. This was
attributable to a higher morning salivary cortisol con-
centration. Cortisol levels follow a strong circadian
rhythm in healthy adults, with the highest levels being
evident in the morning after awakening and the nadir
occurring at around midnight [39]. A pronounced diur-
nal cortisol rhythm was apparent at baseline in our pa-
tient cohort, and this is consistent with previous studies
of non-metastatic breast cancer patients and survivors
[4,5]. However, this is the first study to report a steepening
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in breast cancer patients in the early recovery phase after
treatment. The implications of this are difficult to define
but flatter diurnal cortisol rhythms (blunted morning and/
or elevated evening levels) have been associated with de-
pressive symptoms, poor sleep quality and persistent fa-
tigue after breast cancer treatment [5,40]. Hence, the
intervention may have influenced morning cortisol levels
via its positive impact on one or all of these factors, or via
its impact on other factors not monitored in this study.
Interestingly, an increase in morning cortisol level, accom-
panied by improvements in depressive symptoms and psy-
chological stress, was reported after an 8-week stress
reduction programme involving yoga, meditation and
group discussions in breast cancer patients [33]. This was
interpreted as evidence that the intervention resulted in a
normalisation of the cortisol response. In a similar way,
our results may indicate a modest improvement in HPA
axis regulation in the intervention group but further re-
search is needed to confirm this and delineate the precise
determinants of HPA axis modulation.
Circulating levels of the inflammatory cytokines IL-6
and TNF-α have also been used as evidence of aberrant
HPA axis regulation in breast cancer patients and other
populations [6,7,9]. Depression and psychological stress
are characterised by elevated levels of IL-6 and TNF-α,
[6,41] and IL-6 stimulates cortisol secretion by adreno-
cortical cells [42]. However, in the present study, levels
of these inflammatory cytokines were unchanged at the
6-month follow-up, and this is consistent with previous
lifestyle intervention studies involving breast cancer sur-
vivors [23,24]. Elevated levels of these inflammatory cy-
tokines have more generally been associated with severe
and/or chronic depression and more marked HPA axis
dysregulation in previous studies [6,9]. The pronounced
diurnal cortisol rhythm at baseline in our patient cohort,
coupled with evidence of mild depressive symptoms,
suggests a more modest disruption of HPA axis regula-
tion, which probably explains why the intervention had
no effect on these inflammatory cytokines.
This is also consistent with our results for immune
function. Previous studies show that high levels of stress
and depression, coupled with the persistent activation of
the HPA axis, impair immune responses and potentially
contribute to the development and progression of cancer
(reviewed by Reiche et al. [7]). However, indices of im-
mune function (lymphocyte proliferation and NK cell
cytotoxicity) were unchanged from baseline levels in the
present study. Furthermore, the different pattern of re-
sponse in CD3+CD4+ and CD3+CD8+ T cell counts is
difficult to interpret, as baseline values were higher in
the intervention group. Nevertheless, an increase in total
leukocyte count, attributable to an increase in lymphocyte
and neutrophil counts, was observed in the controls. Theclinical implications of the latter are unknown but surgi-
cally treated early-stage breast cancer patients who experi-
enced disease recurrence exhibited higher lymphocyte and
neutrophil counts relative to disease-free patients in the
17 months prior to recurrence detection [8]. This con-
trasts with earlier evidence of an association between low
lymphocyte counts and breast cancer recurrence [43]. Al-
though changes in circulating leukocyte counts during re-
covery from cancer treatment may be indicative of specific
and/or non-specific immune reactions to sub-clinical dis-
ease [8,43], the clinical significance of such changes in our
patient cohort is difficult to interpret without the longer-
term follow-up of clinical endpoints such as disease-free
interval and mortality.
Conclusions
In conclusion, this study shows for the first time that an
improvement in depressive symptoms resulting from su-
pervised exercise and healthy eating advice in the early
recovery phase, 3 to 18 months, after breast cancer
treatment is accompanied by a significant change in di-
urnal salivary cortisol rhythm. The increase in morning
salivary cortisol at the 6-month follow-up suggests a
normalisation of HPA axis regulation, which may be
linked to the improvement in psychological health sta-
tus. The precise determinants and clinical significance of
these changes warrants further investigation.
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